NASH Phase 2 results imminent --A $20+ BILLION Market

positive results likely to push this stock significantly higher ,,results expected within 4 weeks . The drug is already partnered with pharma giant Boehringer Ingelheim . Competitors like Genfit , Intercept and Madrigal all valued north of US$500+ Million while Pharmaxis has a laughable valuation of only US$ 54 Million . Positive readout could push stock closer to $1 .GL

"SunTrust Robinson Humphrey's analyst Edward Nash, who has called NASH "one of the last untapped multibillion-dollar therapeutic areas," forecasts the space to grow to more than $5 billion in the U.S. alone by 2028. Research and consulting firm GlobalData estimates the NASH space across seven major markets -- the U.S., France, Germany, Italy, Spain, the U.K. and Japan -- is set to rise to $25.3 billion by 2026.

As markets for diseases such as diabetes and hepatitis C become crowded, companies are looking to NASH for their next big break."